Macular Degeneration Treatment Market Report 2026

Macular Degeneration Treatment Market Overview

• Macular Degeneration Treatment market size has reached to $12.38 billion in 2025 • Expected to grow to $20.74 billion in 2030 at a compound annual growth rate (CAGR) of 10.7% • Growth Driver: Growing Retinal Disorder Incidence Propels Macular Degeneration Treatment Market • Market Trend: Biosimilar Advancements in Age-Related Macular Degeneration (AMD) Treatment: FDA Approvals for Yesafili and Opuviz • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Macular Degeneration Treatment Market?

Macula refers to the central portion of the retina, a light-sensitive layer of tissue at the back of the eye. The macula is responsible for central vision. Degeneration of the macula, which affects the central part of the retina (the macula) and results in distortion or loss of central vision, occurs most commonly after the age of 60 and is referred to as age-related macular generation (AMD). The macular degeneration treatment is used to treat macular degeneration eye disease and slow the disease and prevent severe loss of vision. The main disease stages in the macular degeneration treatment market are early-stage AMD, intermediate AMD, and late-stage AMD. In early-stage AMD, the macula changes, with medium-sized drusen deposits and no pigment changes, but this does not impact vision. Intermediate AMD is when vision may get blurry or wavy with large drusen or pigment changes. In late-stage AMD, the central vision fails completely, causing vision loss. The different types of macular degeneration treatments include wet macular degeneration and dry macular degeneration. The different routes of administration of macular degeneration treatment include oral, injectable, and others used by different end-users such as ambulatory surgical centers, ophthalmic clinics, and hospitals.

What Is The Macular Degeneration Treatment Market Growth Forecast?

The macular degeneration treatment market size is expected to see rapid growth in the next few years. It will grow to $20.74 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to rising elderly population worldwide, increasing investment in advanced retinal therapies, growing focus on early-stage amd management, expanding adoption of gene and regenerative therapies, higher healthcare spending on vision care. Major trends in the forecast period include rising focus on early diagnosis and disease progression control, growing adoption of anti-vegf therapies, increasing demand for long-term vision preservation treatments, expansion of minimally invasive treatment options, rising awareness of age-related eye disorders.

Global Macular Degeneration Treatment Market Segmentation

1) By Stage of Disease: Early-Stage AMD, Intermediate AMD, Late-Stage AMD 2) By Route of Administration: Oral, Injectable, Other Routes of Administration 3) By End User: Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals Subsegments: 1) By Early-Stage AMD: Nutritional Supplements, Lifestyle Modification Treatments 2) By Intermediate AMD: Regular Disease Monitoring and Imaging Surveillance, Risk-Factor Management and Lifestyle Modification 3) By Late-Stage AMD: Surgical Treatments, Advanced Anti-VEGF Therapies, Gene Therapy Options

What Is The Driver Of The Macular Degeneration Treatment Market?

The increasing burden of retinal disorders is expected to propel the growth of the macular degeneration treatment market. Retinal disorders affect the vital tissue and affect the way individuals process visual information, leading to distorted or absent vision. For instance, according to the American Academy of Ophthalmology, in 2050, an estimated 7.32 million people in the United States will have primary open-angle glaucoma, a general term used to describe a group of eye disorders, with the highest numbers among populations aged 70 to 79 years (32%), women (50%), and Hispanics (50%). The largest demographic group is Hispanic men. Therefore, the increasing burden of retinal disorders is driving the growth of the macular degeneration treatment industry.

Key Players In The Global Macular Degeneration Treatment Market

Major companies operating in the macular degeneration treatment market are F Hoffmann La Roche Ltd, Regeneron Pharmaceuticals Inc, Novartis AG, Bayer AG, Allergan Inc, Bausch Health Companies Inc, Santen Pharmaceutical Co Ltd, Alimera Sciences Inc, Apellis Pharmaceuticals Inc, Iveric Bio Inc, Aerie Pharmaceuticals Inc, Kodiak Sciences Inc, Neurotech Pharmaceuticals Inc, Regenxbio Inc, Adverum Biotechnologies Inc, Applied Genetic Technologies Corp, 4D Molecular Therapeutics Inc, GenSight Biologics SA, Nanoscope Therapeutics Inc, Annexon Inc, Ocular Therapeutix Inc, Graybug Vision Inc

Global Macular Degeneration Treatment Market Trends and Insights

Major companies operating in the macular degeneration treatment market are focused on developing biosimilars for the treatment of age-related macular degeneration (AMD) to increase accessibility to effective therapies. Biosimilars refer to biological medical products that are highly similar to an already approved reference product, with no clinically meaningful differences in terms of safety, purity, or potency. For instance, in May 2024, Biocon Biologics Ltd, an Indian-based company, and Samsung Bioepis Co. Ltd, a South Korea-based company, recevied FDA Approvals for Yesafili and Opuviz, two new biosimilars. Both biosimilars inhibit vascular endothelial growth factor (VEGF), which is responsible for abnormal blood vessel growth in the eye. This action helps prevent vision loss associated with conditions like AMD and diabetic retinopathy. The FDA's approval process included comparative studies showing that Yesafili and Opuviz have no significant differences in efficacy or safety compared to Eylea. These studies involved rigorous assessments of the biosimilars' pharmacokinetics and immunogenicity.

What Are Latest Mergers And Acquisitions In The Macular Degeneration Treatment Market?

In July 2023, Harrow Inc., a US-based company, acquired Santen for $8 million. With this acquisition, Harrow aims to expand its portfolio by incorporating Santen's expertise in providing macular degeneration treatment. Santen Pharmaceutical Co., Ltd. is a Japan-based company that offers macular degeneration treatment.

Regional Outlook

North America was the largest region in the macular degeneration treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Macular Degeneration Treatment Market?

The macular degeneration treatment market includes revenues earned by entities by anti-angiogenic drugs, photodynamic therapy, laser therapy and low vision aids. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Macular Degeneration Treatment Market Report 2026?

The macular degeneration treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the macular degeneration treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.